Related Experiment Videos
BCR-ABL as a target for novel therapeutic interventions
T Kindler1, R G Meyer, T Fischer
1III. Medical Department (Hematology/Oncology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Expert Opinion on Therapeutic Targets
|March 21, 2002
Summary
The BCR-ABL oncogene drives chronic myeloid leukemia (CML) and other blood cancers. Targeting BCR-ABL offers novel therapeutic strategies for these diseases.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The BCR-ABL oncogene arises from the t(9; 22) translocation.
- BCR-ABL is the primary driver of chronic myeloid leukemia (CML).
- BCR-ABL is also implicated in a subset of acute lymphoblastic leukemias and acute myeloid leukemias.
Purpose of the Study:
- To review molecular targeting strategies for the BCR-ABL oncogene.
- To discuss novel therapeutic approaches based on understanding BCR-ABL pathways.
Main Methods:
- Review of experimental evidence on BCR-ABL's causative role.
- Analysis of molecular mechanisms and downstream pathways of BCR-ABL.
- Discussion of therapeutic strategies including kinase inhibition, antisense, and immunomodulation.
Main Results:
- BCR-ABL is a validated molecular target in CML.
- Elucidation of BCR-ABL pathways has informed drug design.
- Multiple therapeutic strategies are being developed.
Conclusions:
- Targeting BCR-ABL offers promising therapeutic avenues.
- Inhibition of protein tyrosine kinase activity is a key strategy.
- Antisense strategies and immunomodulation are also being explored.